Navigation Links
Abbott Receives European Regulatory Approval for New Ovarian Cancer Diagnostic Test

ABBOTT PARK, Ill., Jan. 14 /PRNewswire-FirstCall/ -- A new diagnostic tool, which studies show can aid in determining the risk of whether a pelvic mass is benign or malignant, is now available in Europe. This simple blood test is expected to help in the assessment of epithelial ovarian cancer, the most lethal form of gynecological cancer. This important immunoassay, which will run on Abbott's ARCHITECT systems, is the first automated HE4 test available anywhere in the world.

Research has shown that this novel diagnostic marker, combined with other tests such as the CA125 assay, can aid in measuring the risk of epithelial ovarian cancer in pre- and post-menopausal women who have a pelvic mass.

According to the International Agency for Research on Cancer, the five-year survival rate of ovarian cancer patients is 46 percent. However, when the disease is diagnosed earlier, the survival rate increases to 94 percent.

"The ability of this test to help physicians predict whether a pelvic mass is benign or malignant is an important development for both patients and physicians," said Michael Warmuth, senior vice president, diagnostics, Abbott. "Abbott's ARCHITECT HE4 test will aid physicians in determining the most appropriate treatment for their patients."

Abbott partnered with Fujirebio Diagnostics, Inc. in the development of the assay. The test is now available in several European countries, as well as in some countries in Asia Pacific and Latin America. The ARCHITECT HE4 Assay was recently submitted to the FDA for 510(k) clearance.

About Ovarian Cancer

Ovarian cancer is the leading cause of death from gynecological cancers and the fifth-leading cause of cancer death in women. An estimated one in 72 women will develop ovarian cancer in her lifetime. It accounts for 31 percent of cancers of the female genital organs. Women who are postmenopausal are at the greatest risk for ovarian cancer.

About Abbott Diagnostics

Abbott Diagnostics is a global leader in in vitro diagnostics and offers a broad range of innovative instrument systems and tests for hospitals, reference labs, blood banks, physician offices and clinics. With more than 69,000 institutional customers in more than 100 countries, Abbott's diagnostic products offer customers automation, convenience, cost effectiveness and flexibility. The history of Abbott Diagnostics is filled with examples of first-of-a-kind products and significant technological advancements, including the development of the very first diagnostic test to detect HIV.

About Abbott

Abbott (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 72,000 people and markets its products in more than 130 countries. Abbott's news releases and other information are available on the company's Web site at




Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Abbott to Provide $1 Million in Funding, Products to Help Address Health Needs in Haiti
2. Feeding America and Abbott Transform Disaster Preparedness Into Hunger Relief
3. Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems
4. Abbott Declares 344th Consecutive Quarterly Dividend
5. Abbott Statement on ARBITER 6 - HALTS Results and Abbotts Niaspan (niacin extended-release)
6. Abbott to Acquire Novel Investigational Biologic to Treat Chronic Pain
7. Abbott Receives Sustainability Award for Continued Efforts to Protect the Environment in Illinois
8. Abbott Again Honored for Offering One of the Top 10 Leading Workplaces
9. Abbott Receives FDA Approval for First Fully Automated Blood Screening Test for HIV-1/HIV-2
10. Abbott Announces TCT 2009 Activities
11. Abbott Expands Use of Sustainable Packaging as Part of Global Environmental Efforts
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... The workstation boundaries ... as IMAGE Information Systems launches MED-TAB™ -- the world’s first portable DICOM-calibrated medical ... November 29 to December 4, 2015. , MED-TAB is expected to change ...
(Date:12/1/2015)... ... 01, 2015 , ... The importance of volumetric breast density ... of numerous abstracts accepted for presentation here, at the 101st Annual Radiology Society ... the use of Volpara Solutions’ quantitative breast imaging software tools for providing breast ...
(Date:12/1/2015)... ... December 01, 2015 , ... For the millions of people ... Incorporated has launched the VaPro Plus Pocket™ touch free hydrophilic intermittent catheter. “Hollister ... free catheter portfolio,” said Michael Gresavage, Vice President North America. "We designed our ...
(Date:12/1/2015)... ... 01, 2015 , ... SAN FRANCISCO, Calif. (December 1, 2015) ... has awarded Education and Developmental Therapies (EDT), an Applied Behavior Analysis (ABA) service ... special needs providers that excel in synthesizing the areas of clinical quality, staff ...
(Date:12/1/2015)... ... December 01, 2015 , ... McLean, ... been awarded a fixed price per sprint agile development contract to support the ... million over five years, provides software engineering, infrastructure, as well as operations and ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... BOSTON , Dec. 1, 2015  Six months of ... adolescents with type 1 diabetes, according to new research from ... . However, it may have a beneficial effect on measures ... the current issue of the Journal of the American ... date examining the effect of metformin on overweight and obese ...
(Date:12/1/2015)... Russia has always been a ... new drugs registered in Europe in 2015 were ... Russia has always been a country of choice ... in Europe in 2015 were tested in phase ... Russia has always been a country of choice for global ...
(Date:12/1/2015)... 1, 2015 Contraceptives ... Contraceptives, Male Condoms, Female Condoms, Intrauterine Devices, ... Diaphragms, Contraceptive Sponges, Non-Surgical Permanent Contraception Devices) ... Trends and Forecast 2014 - 2020 ", ... (TMR).The report states that the global contraceptives ...
Breaking Medicine Technology: